Meeting Coverage

Study demonstrates that stable BTT patients with second-generation VADs (I5.5) can be safely transitioned from ICU to step-down units, alleviating ICU congestion and providing significant financial benefits.

Researchers called for dermatologists to recognize psoriasis-associated comorbidities, which can be managed more effectively with a multidisciplinary care team.

Collaborating with patients is essential for addressing sleep disturbances and mental health comorbidities, which are under-recognized in psoriasis.

ESK-001, a TYK2 inhibitor, showed promising efficacy and good tolerability in phase 2 for plaque psoriasis, prompting a phase 3 trial.

Patients with melanoma and cIRAEs on immune checkpoint inhibitors face higher toxicity risks but improved survival, warranting close monitoring.

Bempikibart demonstrated durable, clinically meaningful responses in patients with severe alopecia areata in the phase 2 SIGNAL-AA trial.

A recently developed treatment satisfaction tool called the DermSat-7 was valid and reliable for use in psoriasis management and clinical trials.

Research presented at ACC.25 focused on coordination teams and new hospital workflows designed to improve referrals and care quality for cardiology patients.

A digital monitoring program reduced readmission rates and bolstered cardiac rehabilitation enrollment among patients with coronary heart disease.

New research will be presented at ACC.25, including data on smart blood pressure monitor utilization and arterial stiffness in patients with hypertension.

The upcoming 2025 ACC conference, will showcase insights from specialists and focus on transforming cardiovascular care for all.

At the 2025 Winter Clinical Dermatology Conference, Ronald Vender, MD, discussed a psoriasis treatment goal algorithm for patients having inadequate response.

Baricitinib significantly improved scalp hair regrowth, with 80% or more scalp hair coverage in 42% of adolescents with severe alopecia areata (AA) at 36 weeks, with a favorable safety profile. Similarly, eyebrow and eyelash regrowth were also significantly improved.

Once-daily ICP-488, a selective oral tyrosine kinase 2 (TYK2) inhibitor, significantly improved PASI scores in patients with moderate-to-severe plaque psoriasis compared with placebo at week 12, with a safety profile similar to placebo.

New findings from the phase 3 ICONIC-LEAD trial suggest that once-daily oral icotrokinra demonstrated significant, durable skin clearance and a safety profile similar to placebo in patients with plaque psoriasis.

Upadacitinib efficacy and safety in treating palmoplantar pustulosis (PPP) revealed rapid and sustained pustule clearance with an acceptable safety profile. The researchers also introduced a novel mouse model to further advance PPP research by providing insights into disease mechanisms and potential treatment targets.

The phase 3 ROCKET-Horizon trial testing rocatinlimab, a first-in-class investigational T-cell rebalancing therapy, meets its co-primary end points in week 24: EASI75 response was 32.8% for rocatinlimab versus 13.7% for moderate-to-severe atopic dermatitis (AD).

Data from the Swiss Psoriasis Registry and the EuroGuiDerm guidelines highlight sex differences in psoriasis and the impact on health-related quality of life.

A new study suggests inadequate counseling and limited resources are among several barriers to educating patients on psoriasis’s link to cardiometabolic issues.